去势抵抗性前列腺癌预后生物标志物研究进展

Research Progress in Prognostic Biomarkers of Castration-Resistant Prostate Cancer

近年前列腺癌的发病率逐年上升,治疗初期绝大多数前列腺癌患者可通过内分泌治疗获益,但随着肿瘤细胞对内分泌药物敏感性的降低,前列腺癌逐步进展为激素非依赖性前列腺癌。去势抵抗性前列腺癌(CRPC)患者的发病年龄、疾病阶段、疾病的治疗手段等均可影响患者的预后,但目前尚缺乏特异性、敏感性指标指导临床早期干预。深入研究CRPC的预后生物标志物,可以指导临床及早干预,达到延长CRPC患者预后生存时间、提高生活质量的目的。

The incidence of prostate cancer is increasing year by year.At the beginning, most of the patients with prostate cancer can benefit from endocrine therapy, however, as the treatment progresses, prostate cancer will gradually lose its sensitivity to endocrine drugs, and progressively develop into hormone independent prostate cancer.The age of onset, stage of disease and treatment of castration resistant prostate cancer(CRPC) all have an impact on the prognosis of the patients, but the specific and sensitive indicators to guide clinical early intervention are still lacking.Further study on the prognostic biomarkers of CRPC can guide the early clinical intervention, prolong the survival time and improve the quality of life of the patients with CRPC.